Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of olaparib following adjuvant chemotherapy in patients with resected pancreatic cancer with a BRCA 1, BCRA 2 or PALB2 mutation through germline testing.

General Information

NCT#: NCT04858334
Study ID: NCI-2020-05659
Trial Phase: Phase II

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Olaparib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search